Rangi Kandane-Rathnayake
Overview
Explore the profile of Rangi Kandane-Rathnayake including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
555
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hao Y, Hansen D, Louthrenoo W, Chen Y, Cho J, Lateef A, et al.
ACR Open Rheumatol
. 2025 Feb;
7(3):e70007.
PMID: 40012261
Objective: In contrast to relapsing-remitting patterns, persistently active disease (PAD) is a disease activity pattern in patients with systemic lupus erythematosus (SLE) that is inadequately studied. We sought to identify...
2.
Li N, Hoi A, Luo S, Wu Y, Louthrenoo W, Golder V, et al.
Lupus Sci Med
. 2025 Feb;
12(1).
PMID: 39939124
Objective: Disease activity both between and within patients with SLE is highly variable, yet factors driving this variability remain unclear. This study aimed to identify predictors of variability in SLE...
3.
Kandane-Rathnayake R, Milea D, Louthrenoo W, Hoi A, Golder V, Cho J, et al.
Lupus Sci Med
. 2025 Jan;
12(1.
PMID: 39832908
Objective: To estimate the prevalence of organ damage (damage) and flare and to examine longitudinal associations between flares and subsequent damage accrual, in patients with systemic lupus erythematosus (SLE). Methods:...
4.
Kandane-Rathnayake R, Golder V, Louthrenoo W, Chen Y, Cho J, Lateef A, et al.
Rheumatology (Oxford)
. 2024 Dec;
PMID: 39656834
Objective: High disease activity status (HDAS) in patients with systemic lupus erythematosus (SLE) is associated with adverse long-term outcomes. We examined the frequency of lupus low disease activity state (LLDAS)...
5.
Hao Y, Hansen D, Louthrenoo W, Chen Y, Cho J, Lateef A, et al.
Lupus Sci Med
. 2024 Sep;
11(2).
PMID: 39299757
Objectives: The lupus low disease activity state (LLDAS) allows for certain clinical and/or serological activity of SLE, provided overall disease activity does not exceed predefined cut-offs. This study aimed to...
6.
Eades L, Hoi A, Liddle R, Sines J, Kandane-Rathnayake R, Khetan S, et al.
Lancet Rheumatol
. 2024 Jul;
6(10):e713-e726.
PMID: 38971169
The first inhabitants of Australia and the traditional owners of Australian lands are the Aboriginal and Torres Strait Islander peoples. Aboriginal and Torres Strait Islander peoples are two to four...
7.
Golder V, Kandane-Rathnayake R, Li N, Louthrenoo W, Chen Y, Cho J, et al.
Lancet Rheumatol
. 2024 Jun;
6(8):e528-e536.
PMID: 38876129
Background: Validation of protective associations of the lupus low disease activity state (LLDAS) against flare, irreversible damage, health-related quality of life, and mortality has enabled the adoption of treat-to-target strategies...
8.
Parra Sanchez A, van Vollenhoven R, Morand E, Bruce I, Kandane-Rathnayake R, Weiss G, et al.
Rheumatol Ther
. 2024 Jun;
11(4):1059-1061.
PMID: 38847996
No abstract available.
9.
de Luca Montes R, Huq M, Godfrey T, Oon S, Calderone A, Kandane-Rathnayake R, et al.
Adv Rheumatol
. 2024 May;
64(1):38.
PMID: 38720354
Background: This study examines the association of standard-of-care systemic lupus erythematosus (SLE) medications with key outcomes such as low disease activity attainment, flares, damage accrual, and steroid-sparing, for which there...
10.
Power B, Kandane-Rathnayake R, Tiller G, Renton W, Cox A, Johnstone L, et al.
Lupus
. 2024 Apr;
33(7):749-758.
PMID: 38587355
Introduction: We aim to report on the feasibility of establishment of the first paediatric cohort as part of the longitudinal database of the Australian Lupus Registry and Biobank (ALRB) and...